111 related articles for article (PubMed ID: 8671476)
1. Subtle progesterone rise after the administration of the gonadotrophin-releasing hormone antagonist cetrorelix in intracytoplasmic sperm injection cycles.
Ubaldi F; Albano C; Peukert M; Riethmuller-Winzen H; Camus M; Smitz J; Van Steirteghem A; Devroey P
Hum Reprod; 1996 Jul; 11(7):1405-7. PubMed ID: 8671476
[TBL] [Abstract][Full Text] [Related]
2. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation.
Rongières-Bertrand C; Olivennes F; Righini C; Fanchin R; Taïeb J; Hamamah S; Bouchard P; Frydman R
Hum Reprod; 1999 Mar; 14(3):683-8. PubMed ID: 10221695
[TBL] [Abstract][Full Text] [Related]
3. Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.
Seow KM; Lin YH; Huang LW; Hsieh BC; Huang SC; Chen CY; Chen PH; Tzeng CR; Hwang JL
Gynecol Endocrinol; 2007 Jun; 23(6):338-42. PubMed ID: 17616858
[TBL] [Abstract][Full Text] [Related]
4. Hormonal profile during the follicular phase in cycles stimulated with a combination of human menopausal gonadotrophin and gonadotrophin-releasing hormone antagonist (Cetrorelix).
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Siebert-Weigel M; Diedrich K; Van Steirteghem AC; Devroey P
Hum Reprod; 1996 Oct; 11(10):2114-8. PubMed ID: 8943511
[TBL] [Abstract][Full Text] [Related]
5. Oocyte and embryo quality as well as pregnancy rate in intracytoplasmic sperm injection are not affected by high follicular phase serum progesterone.
Ubaldi F; Smitz J; Wisanto A; Joris H; Schiettecatte J; Derde MP; Borkham E; Van Steirteghem A; Devroey P
Hum Reprod; 1995 Dec; 10(12):3091-6. PubMed ID: 8822420
[TBL] [Abstract][Full Text] [Related]
6. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.
Albano C; Smitz J; Camus M; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Fertil Steril; 1997 May; 67(5):917-22. PubMed ID: 9130900
[TBL] [Abstract][Full Text] [Related]
7. Luteal phase and clinical outcome after human menopausal gonadotrophin/gonadotrophin releasing hormone antagonist treatment for ovarian stimulation in in-vitro fertilization/intracytoplasmic sperm injection cycles.
Albano C; Smitz J; Tournaye H; Riethmüller-Winzen H; Van Steirteghem A; Devroey P
Hum Reprod; 1999 Jun; 14(6):1426-30. PubMed ID: 10357952
[TBL] [Abstract][Full Text] [Related]
8. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group.
Albano C; Felberbaum RE; Smitz J; Riethmüller-Winzen H; Engel J; Diedrich K; Devroey P
Hum Reprod; 2000 Mar; 15(3):526-31. PubMed ID: 10686191
[TBL] [Abstract][Full Text] [Related]
9. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.
Diedrich K; Diedrich C; Santos E; Zoll C; al-Hasani S; Reissmann T; Krebs D; Klingmüller D
Hum Reprod; 1994 May; 9(5):788-91. PubMed ID: 7929723
[TBL] [Abstract][Full Text] [Related]
11. Reduced implantation rate associated with a subtle rise in serum progesterone concentration during the follicular phase of cycles stimulated with a combination of a gonadotrophin-releasing hormone agonist and gonadotrophin.
Harada T; Yoshida S; Katagiri C; Takao N; Ikenari T; Toda T; Mio Y; Terakawa N
Hum Reprod; 1995 May; 10(5):1060-4. PubMed ID: 7657741
[TBL] [Abstract][Full Text] [Related]
12. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
13. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
14. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
[TBL] [Abstract][Full Text] [Related]
15. Premature luteinization in in vitro fertilization cycles using gonadotropin-releasing hormone agonist (GnRH-a) and recombinant follicle-stimulating hormone (FSH) and GnRH-a and urinary FSH.
Ubaldi F; Camus M; Smitz J; Bennink HC; Van Steirteghem A; Devroey P
Fertil Steril; 1996 Aug; 66(2):275-80. PubMed ID: 8690116
[TBL] [Abstract][Full Text] [Related]
16. Initiation of high dose gonadotrophin-releasing hormone antagonist treatment during the late follicular phase in the macaque abolishes luteal function irrespective of effects upon the luteinizing hormone surge.
Fraser HM; Lunn SF; Morris KD; Deghenghi R
Hum Reprod; 1997 Mar; 12(3):430-5. PubMed ID: 9130734
[TBL] [Abstract][Full Text] [Related]
17. The synergistic effects of clomiphene citrate and human menopausal gonadotrophin in the folliculogenesis of stimulated cycles as assessed by the gonadotrophin-releasing hormone antagonist Nal-Glu.
Cassidenti DL; Paulson RJ; Lobo RA; Sauer MV
Hum Reprod; 1992 Mar; 7(3):344-8. PubMed ID: 1587939
[TBL] [Abstract][Full Text] [Related]
18. Human ovarian steroid secretion in vivo: effects of GnRH agonist versus antagonist (cetrorelix).
Garcia-Velasco JA; Isaza V; Vidal C; Landazábal A; Remohí J; Simón C; Pellicer A
Hum Reprod; 2001 Dec; 16(12):2533-9. PubMed ID: 11726570
[TBL] [Abstract][Full Text] [Related]
19. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers.
Duijkers IJ; Klipping C; Willemsen WN; Krone D; Schneider E; Niebch G; Hermann R
Hum Reprod; 1998 Sep; 13(9):2392-8. PubMed ID: 9806255
[TBL] [Abstract][Full Text] [Related]
20. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
